We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Name | Symbol | Market | Type |
---|---|---|---|
AstraZeneca PLC | NASDAQ:AZN | NASDAQ | Depository Receipt |
Price Change | % Change | Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
0.75 | 0.99% | 76.55 | 55.00 | 77.24 | 76.49 | 75.43 | 76.47 | 9,026,349 | 05:00:07 |
By Elena Vardon
AstraZeneca PLC on Monday said its cancer drug Enhertu has shown clinically meaningful and durable responses across multiple HER2-expressing advanced solid tumors in its DESTINY-PanTumor02 Phase II trial.
The Anglo-Swedish pharma major said Enhertu--trastuzumab deruxtecan, which it is jointly developing and commercializing with Daiichi Sankyo--had met prespecified criteria for objective response rate and duration of response.
"Enhertu has already demonstrated its potential to improve outcomes for patients with HER2-targetable breast, gastric and lung cancers, and these positive initial results in other tumor settings with significant unmet need are very encouraging," said Chief Medical Officer and Oncology Chief Development Officer Cristian Massacesi.
Write to Elena Vardon at elena.vardon@wsj.com
(END) Dow Jones Newswires
March 06, 2023 02:26 ET (07:26 GMT)
Copyright (c) 2023 Dow Jones & Company, Inc.
1 Year AstraZeneca Chart |
1 Month AstraZeneca Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions